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Objectives The goal of this study was to evaluate shorter duration (3 months) dual antiplatelet therapy (DAPT) after drug-
eluting stent (DES) implantation.
Background There have been few published reports of prospective randomized clinical studies comparing the safety and effi-
cacy of shorter duration DAPT after DES implantation.
Methods We randomly assigned 2,117 patients with coronary artery stenosis into 2 groups according to DAPT duration
and stent type: 3-month DAPT following Endeavor zotarolimus-eluting stent (E-ZES) implantation (E-ZES
3-month DAPT, n  1,059) versus 12-month DAPT following the other DES implantation (standard therapy,
n  1,058). We hypothesized that the E-ZES3-month DAPT would be noninferior to the standard therapy for
the primary composite endpoint (cardiovascular death, myocardial infarction, stent thrombosis, target\vessel
revascularization, or bleeding) at 1 year.
Results The primary endpoint occurred in 40 (4.7%) patients assigned to E-ZES3-month DAPT compared with 41
(4.7%) patients assigned to the standard therapy (difference: 0.0%; 95% confidence interval [CI]: 2.5 to 2.5;
p  0.84; p  0.001 for noninferiority). The composite rates of any death, myocardial infarction, or stent throm-
bosis were 0.8% and 1.3%, respectively (difference: 0.5%; 95% CI: 1.5 to 0.5; p  0.48). The rates of stent
thrombosis were 0.2% and 0.3%, respectively (difference: 0.1%; 95% CI: 0.5 to 0.3; p  0.65) without its
further occurrence after cessation of clopidogrel in the E-ZES3-month DAPT group. The rates of target vessel
revascularization were 3.9% and 3.7%, respectively (difference: 0.2%; 95% CI: 2.3 to 2.6; p  0.70).
Conclusions E-ZES3-month DAPT was noninferior to the standard therapy with respect to the occurrence of the primary end-
point. (REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following E-ZES implantation [RESET];
NCT01145079) (J Am Coll Cardiol 2012;60:1340–8) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.043Because one of the strong predictors for stent thrombosis is
early discontinuation of clopidogrel (1,2), prolonged dual
antiplatelet therapy (DAPT) is highly recommended to
prevent stent thrombosis (1,3). However, reports from
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duration of DAPT (4–6). One optical coherence tomography
study reported sufficient strut coverage following implanta-
tion with the E-ZES as early as 3 months post-procedure
(7). A recent registry study with 661 low-risk patients who
received DAPT for 3 months following E-ZES implanta-
tion showed favorable long-term clinical outcomes and lower
incidence of stent thrombosis after cessation of clopidogrel 3
months post-intervention (8). On the basis of the safety nature
of E-ZES and theoretical backgrounds from the imaging and
clinical studies, we hypothesized that 3-month DAPT after
E-ZES implantation (E-ZES3-month DAPT) may be
noninferior to 12-month DAPT after implantation with other
drug-eluting stent (DES) (standard therapy). In the RESET
(REal Safety and Efficacy of a 3-month dual antiplatelet
Therapy following E-ZES implantation) trial, we compared
the safety and efficacy between patients treated with
E-ZES3-month DAPT and patients treated with the stan-
dard therapy.
Methods
The RESET trial was a prospective, open-label, randomized
trial conducted at 26 sites in Korea; the complete lists and
detailed information regarding participating institutes appear
in the Online Appendix. The trial protocol was approved by
the institutional review board at each participating center.
Figure 1 Diagram for Study Design and the Detailed Enrollmen
DAPT  dual antiplatelet therapy; DES  drug-eluting stent; EES  everolimus-elu
R-ZES  Resolute zotarolimus-eluting stent(s); SES  sirolimus-eluting stent(s).Patients with a diagnosis of
angina or acute myocardial in-
farction with more than 50% di-
ameter stenosis in a coronary ar-
tery by visual estimation, who
presented to the catheterization
laboratory for elective percutane-
ous coronary intervention, were
eligible for participation. The
complete inclusion and exclusion
criteria are provided in the Online Appendix. All study
participants provided written informed consent using doc-
uments approved by the local ethics board.
Using an interactive web-based response system, study
participants were randomly assigned in a 1:1 ratio to receive
either the E-ZES or another currently available DES.
Randomization was stratified by participating center and 4
clinical or lesion characteristics (Fig. 1): diabetes mellitus,
acute coronary syndrome, treatment of a short lesion (stent
length 24 mm); and treatment of a long lesion (stent
length 28 mm). Patients with diabetes mellitus or acute
coronary syndrome were randomized to either the E-ZES
or the Resolute zotarolimus-eluting stent (Medtronic);
patients with short lesions to the E-ZES or the Cypher
Select sirolimus-eluting stent (Cordis, Miami, Florida);
and those with long lesions to the E-ZES or the Xience V
atients
ent(s); E-ZES  Endeavor zotarolimus-eluting stent(s);
Abbreviations
and Acronyms
CI  confidence interval
DAPT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
E-ZES  Endeavor
zotarolimus-eluting stent(s)t of P
ting st
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California).
After stent implantation, 100-mg daily aspirin was pre-
scribed indefinitely, and the duration of clopidogrel 75-mg
Baseline Clinical, Angiographic, and ProceduralTable 1 Baseline Clinical, Angiographic, and
Variables E
Duration of DAPT, days
Clinical characteristics
n
Age, yrs
Male
Body mass index, kg/m2
Hypertension
Diabetes mellitus
Dyslipidemia
Current smoker
Congestive heart failure
Ejection fraction, %
Prior myocardial infarction
Prior percutaneous coronary intervention
Prior coronary bypass surgery
Clinical presentation
Stable angina
Unstable angina
Acute myocardial infarction
No. of diseased vessels
1
2
3
Medications at discharge
Statins
Beta-blockers
Angiotensin-converting enzyme inhibitors
Angiotensin receptor blockers
Calcium channel blocker
Angiographic and procedural characteristics
No. of lesions
Treated vessel
Left anterior descending artery
Left circumflex artery
Right coronary artery
ACC/AHA class B2/C
Lesion length, mm
Type of drug-eluting stent
E-ZES
Cypher sirolimus-eluting stents
Xience everolimus-eluting stents
Resolute zotarolimus-eluting stents
Multivessel intervention/patients
Number of lesions per patient
Stent diameter, mm
Stent length per lesion, mm
Adjuvant post-dilation
Maximum stent pressure, atm
Use of glycoprotein IIb/IIIa inhibitors/patient
Procedure successdaily was given depending on the randomization scheme(Fig. 1). Details of study procedures and quantitative coronary
angiographic analyses are provided in the Online Appendix.
Post-procedure clinical assessment was performed in-
hospital, and after 1, 3, 6, and 12 months, either by clinic
acteristicscedural Characteristics
3-Month DAPT Standard Therapy p Value
3 28 364 31 0.001
1,059 1,058
.4 9.4 62.4 9.8 0.94
82 (64.4) 665 (62.9) 0.47
.0 3.2 24.9 3.1 0.50
60 (62.3) 650 (61.4) 0.69
16 (29.8) 305 (28.8) 0.63
11 (57.7) 634 (59.9) 0.31
67 (25.2) 241 (22.8) 0.20
20 (11.3) 125 (11.8) 0.74
.2 9.4 63.9 9.4 0.45
19 (1.8) 17 (1.6) 0.87
37 (3.5) 32 (3.0) 0.63
2 (0.2) 6 (0.6) 0.18
0.66
71 (44.5) 490 (46.3)
32 (40.8) 422 (39.9)
56 (14.7) 146 (13.8)
0.99
03 (56.9) 604 (57.1)
92 (27.6) 292 (27.6)
64 (15.5) 162 (15.3)
23 (87.2) 914 (86.4) 0.61
12 (67.2) 730 (69.0) 0.40
31 (31.3) 349 (33.0) 0.40
23 (30.5) 301 (28.4) 0.32
89 (36.7) 389 (36.8) 1.00
1,341 1,346
0.54
07 (52.7) 722 (53.6)
81 (21.0) 259 (19.2)
53 (26.3) 365 (27.1)
10 (67.9) 932 (69.2) 0.46
.6 10.1 20.1 10.8 0.21
41 (100.0) —
— 383 (28.5)
— 404 (30.0)
— 559 (41.5)
33 (22.0) 248 (23.4) 0.44
7 0.53 1.27 0.68 0.88
8 0.42 3.17 0.83 0.63
.7 10.1 22.9 10.7 0.35
39 (40.2) 540 (40.1) 0.97
.2 3.7 16.5 3.6 0.35
20 (1.9) 21 (2.0) 0.89
39 (99.9) 1,345 (99.9) 0.63
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infarction, stent thrombosis, ischemia-driven target-vessel re-
vascularization, or bleeding at 1-year post-procedure. Clinical
events are defined according to the Academic Research Con-
sortium (9). Detailed definitions of study endpoints, clinical
diseases, and procedural findings are provided in the Online
Appendix. All clinical events were independently monitored
and assessed by a clinical event committee, comprising mem-
bers masked as to the assigned therapy groups.
The primary analysis was a noninferiority comparison
between the 2 groups with respect to the occurrence of the
primary endpoint. On the basis of the previous studies, we
assumed the overall incidence of the primary endpoint after
E-ZES3-month DAPT, and after the standard therapy,
would be 10% and 11%, respectively (4–6,10–12). We
hypothesized that the clinical outcome of E-ZES3-month
APT would be noninferior to the other group, with a
oninferiority margin of 4% for the absolute difference in risk
t 12 months. Assuming a 10% dropout rate, this required an
stimated sample size of 2,120 patients (1,060 for each group)
o achieve 80% power for the noninferiority test and a 1-sided
ype I error of 5%. The detailed methods of statistical analysis
re provided in the Online Appendix.
esults
etween April 2009 and December 2010, we enrolled and
andomized 2,148 patients, of which 2,117 patients
E-ZES3-month DAPT  1,059; standard therapy 
,058) comprised the analysis population. The study design
nd the detailed enrollment of patients are provided in
igure 1. The baseline characteristics were similar between
he 2 groups (Table 1). Clinical follow-up at 1 year was
ompleted for 2,086 of 2,117 patients (98.5%): 1,044 of
,059 patients (98.6%) in E-ZES3-month DAPT group,
nd 1,042 of 1,058 patients (98.5%) in standard therapy
roup (p  0.99). Clinical outcomes through 1-year
ollow-up are listed in Table 2. At 1 year, the E-ZES3-
ContinuedTable 1 Continued
Variables E-ZES3
Quantitative angiographic analysis
Pre-intervention
Reference vessel diameter, mm 3.0
Minimum luminal diameter, mm 1.1
Percent diameter stenosis, % 65.0
Post-intervention
Minimum luminal diameter, mm
In-stent 2.7
In-segment 2.2
Percent diameter stenosis, %
In-stent 11.2
In-segment 30.7
Values are mean  SD, n, or n (%).
ACC  American College of Cardiology; AHA  American Heart As
eluting stent(s).onth DAPT group was noninferior to the standard Hherapy group for the primary endpoint (cumulative events:
0 [4.7%] vs. 41 [4.7%]; difference: 0.0%, 95% confidence
nterval [CI]: 2.5 to 2.5; p  0.84; p  0.001 for
oninferiority) (Fig. 2A). The cumulative events rates of the
omposite of any death, myocardial infarction, or stent
hrombosis were 0.8% and 1.3%, respectively (difference:
0.5%; 95% CI: 1.5 to 0.5; p  0.48, Fig. 2B). The
ccurrence of stent thrombosis was similar between the 2
roups (0.2% vs. 0.3%; difference: 0.1%; 95% CI: 0.5 to
.3; p  0.65). From 3 months through 12 months
ollowing the index procedure, there were 3 stent thrombosis
vents in the standard therapy group, and none in the
-ZES3-month DAPT group despite the cessation of
lopidogrel. The rates of target-vessel revascularization were
.9% for the E-ZES3-month DAPT group and 3.7% for
he standard therapy group. The subgroup analysis of the
rimary endpoint and other events at 1 year is shown in Figure 3
nd Table 2.
Interruption of the DAPT regimen occurred in 62 (5.9%)
f 1,059 patients who were allocated to E-ZES3-month
APT (mean duration of DAPT: 196 63 days). Reasons for
nterruption of the DAPT regimen were as follows: physicians’
istake or failure of monitoring (n  26), physicians’ discre-
ion (n  22), patients’ disagreement (n  13), and repeat
evascularization (n 1). After censoring patients who had an
nterruption of DAPT duration in the E-ZES3-month
APT group, there were no significant differences in 1-year
linical outcomes between the 2 groups (Tables 3 and 4).
iscussion
his randomized study demonstrated that E-ZES3-
onth DAPT is safe and noninferior to the standard
herapy for the primary composite endpoint.
Regardless of DES types, current recommendations call
or a minimum of 12 months of DAPT after DES implan-
ation for the prevention of late stent thrombosis (3).
h DAPT Standard Therapy p Value
3.0 0.5 0.13
1.0 0.5 0.23
.1 65.5 13.8 0.36
2.7 0.4 0.28
2.1 0.5 0.58
11.1 8.1 0.65
.7 30.7 11.7 0.83
n; DAPT  dual antiplatelet therapy; E-ZES  Endeavor zotarolimus--Mont
 0.5
 0.5
 14
 0.4
 0.5
 7.8
 11owever, prolonged DAPT has been associated with
f event
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aspirin alone; reported incidence of major and minor bleed-
Clinical Outcomes Through 1 YearTable 2 Clinical Outcomes Through 1 Year
Variables
E-ZES3-Mo
(n  1,0
Composite events
Primary endpoint 40 (4.
Death from any cause, myocardial
infarction, or stent thrombosis
8 (0.
Death from cardiovascular cause or
myocardial infarction
4 (0.
Each component
Death
From any cause 5 (0.
From cardiovascular cause 2 (0.
Myocardial infarction 2 (0.
Target vessel revascularization 31 (3.
Non–target vessel revascularization 15 (1.
Stent thrombosis, definite or probable 2 (0.
1 month 2
1–3 months 0
3–12 months 0
Bleeding
Major or minor 5 (0.
Major 2 (0.
Cerebrovascular accidents 6 (0.
Subgroup analysis
Diabetes mellitus subset 146
Primary endpoint 4 (2.
Death from cardiovascular cause 1 (0.
Myocardial infarction 0 (0.
Target vessel revascularization 3 (2.
Stent thrombosis, definite or probable 0 (0.
Bleeding, major or minor 0 (0.
Acute coronary syndrome subset, n 301
Primary endpoint 12 (6.
Death from cardiovascular cause 1 (0.
Myocardial infarction 0 (0.
Target vessel revascularization 9 (5.
Stent thrombosis, definite or probable 1 (0.
Bleeding, major or minor 2 (0.
Short-lesion drug-eluting stent subset, n 341
Primary endpoint 9 (2.
Death from cardiovascular cause 0 (0.
Myocardial infarction 1 (0.
Target–vessel revascularization 6 (1.
Stent thrombosis, definite or probable 0 (0.
Bleeding, major or minor 2 (0.
Long-lesion drug-eluting stent subset, n 271
Primary endpoint 15 (7.
Death from cardiovascular cause 0 (0.
Myocardial infarction 1 (0.
Target vessel revascularization 13 (6.
Stent thrombosis, definite or probable 1 (0.
Bleeding, major or minor 1 (0.
Values are the number of events and the cumulative event rate (%). *p
event in either group, the confidence interval (CI) of the differences o
Abbreviations as in Table 1.ing were 1.8% to 3.7% and 1.7% to 5.1%, respectively(13,14). In addition, nuisance bleeding is common in
patients on prolonged DAPT post-DES implantation
PT Standard Therapy
(n  1,058) Difference (95% CI) p Value
41 (4.7) 0.0% (2.5 to 2.5) 0.84
11 (1.3) 0.5% (1.5 to 0.5) 0.48
7 (0.7) 0.3% (1.0 to 0.4) 0.36
8 (1.0) 0.5% (1.4 to 0.4) 0.39
4 (0.4) 0.2% (0.6 to 0.3) 0.41
4 (0.4) 0.2% (0.7 to 0.3) 0.41
27 (3.7) 0.2% (2.3 to 2.6) 0.70
11 (1.5) 0.0% (1.3 to 1.4) 0.52
3 (0.3) 0.1% (0.5 to 0.3) 0.65
0
0
3
10 (1.0) 0.5% (1.2 to 0.2) 0.20
6 (0.6) 0.4% (0.9 to 0.1) 0.16
6 (0.7) 0.1% (0.1 to 1.0) 0.96
146 — —
5 (3.4) 0.6% (4.6 to 3.3) 0.74
1 (0.7) 0.0% (1.9 to 1.9) 1.00
1 (0.7) 0.32
2 (1.4) 0.7% (2.3 to 3.7) 0.65
1 (0.7) 0.32
2 (1.4) 0.16
300 — —
6 (2.0) 4.4% (1.4 to 10.2) 0.16
0 (0.0) 0.32
0 (0.0) 1.00
2 (0.7) 4.7% (0.8 to 10.1) 0.04
0 (0.0) 0.9% (5.1 to 3.4) 0.32
4 (1.3) 0.7% (2.3 to 0.9) 0.41
340 — —
8 (4.1) 1.5% (5.3 to 2.4) 0.86
2 (0.6) 0.16
2 (0.6) 0.3% (1.3 to 0.7) 0.60
6 (3.6) 1.8% (5.5 to 1.9) 0.91
1 (0.3) 0.32
0 (0.0) 0.16
272 — —
22 (8.4) 1.2% (6.6 to 4.3) 0.22
1 (0.4) 0.32
1 (0.4) 0.0% (1.0 to 1.0) 0.99
17 (7.8) 1.4% (7.2 to 4.3) 0.40
1 (0.4) 0.0% (1.0 to 1.0) 0.99
4 (1.5) 1.1% (2.7 to 0.5) 0.18
were calculated with the use of the log-rank test. In case of no clinical
rates could not be calculated.nth DA
59)
7)
8)
4)
5)
2)
2)
9)
5)
2)
5)
2)
6)
8)
7)
0)
1)
0)
0)
5)
3)
0)
4)
3)
7)
7)
0)
3)
8)
0)
6)
2)
0)
4)
3)
4)
4)
values(28.9% of 2,948 patients) (14). The higher incidence of
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result in premature discontinuation of DAPT.
A previous randomized study reported that the use of
DAPT for a period longer than 12 months in patients who
had received DESs was not significantly more effective than
Figure 2 Cumulative Event Rates Using the Kaplan-Meier Meth
A primary endpoint (A), and a composite of death from any cause, myocardial infa
Figure 3 Subgroup Analysis of the Primary Endpoint at 1 Year
CI  confidence interval; other abbreviations as in Figure 1.aspirin monotherapy in reducing the rate of myocardial
infarction or death from cardiac causes (15). In addition,
recent randomized trials showed no clinical benefits of
prolonged DAPT compared with 6-month DAPT after
DES implantation (16,17).
or stent thrombosis (B). Abbreviations as in Figure 1.od
rction,
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efficacy are desirable, especially for those who may need to
stop DAPT early after DES implantation (5,6). The
Baseline Clinical and Angiographic Characteristof Both Groups on a Per Protocol AnalysisTable 3 Baseli e Clin cal and giograph cof Both Groups on a Per Protocol A
Variables E-Z
Clinical characteristics
n
Age, yrs
Male
Body mass index, kg/m2
Hypertension
Diabetes mellitus
Dyslipidemia
Current smoker
Congestive heart failure
Ejection fraction, %
Prior myocardial infarction
Prior percutaneous coronary intervention
Prior coronary bypass surgery
Clinical presentation
Stable angina
Unstable angina
Acute myocardial infarction
No. of diseased vessels
1
2
3
Medications at discharge
Statins
Beta-blockers
Angiotensin-converting enzyme
inhibitors
Angiotensin receptor blockers
Calcium channel blocker
Angiographic characteristics
No. of lesions
Treated vessel
Left anterior descending artery
Left circumflex artery
Right coronary artery
ACC/AHA lesion class B2 or C
Lesion length, mm
Type of drug-eluting stent
E-ZES
Cypher sirolimus-eluting stents
Xience everolimus-eluting stents
Resolute zotarolimus-eluting stents
Multivessel intervention/patients
Total no. of lesions per patient
Stent diameter, mm
Stent length per lesion, mm
Adjuvant post-dilation
Maximum stent pressure, atm
Use of glycoprotein IIb/IIIa inhibitors/patient
Procedure successE-ZES comprises a cobalt alloy, thin-strut stent with abiocompatible phosphorylcholine polymer (4–6). A recent
study reported that among 2,032 patients treated with
E-ZES in 5 trials, Academic Research Consortium–defined
acteristics
is
-Month DAPT Standard Therapy p Value
997 1,058
 9.4 62.4 9.8 0.93
7 (64.9) 665 (62.9) 0.36
 3.2 24.9 3.1 0.47
4 (62.6) 650 (61.4) 0.62
0 (30.1) 305 (28.8) 0.53
0 (58.2) 634 (59.9) 0.45
9 (25.0) 241 (22.8) 0.23
0 (10.0) 125 (11.8) 0.20
 9.2 63.9 9.4 0.33
8 (1.8) 17 (1.6) 0.74
7 (3.7) 32 (3.0) 0.39
2 (0.2) 6 (0.6) 0.29
0.84
3 (45.4) 490 (46.3)
8 (39.9) 422 (39.9)
6 (14.6) 146 (13.8)
0.88
6 (57.8) 604 (57.1)
1 (27.2) 292 (27.6)
0 (15.0) 162 (15.3)
4 (87.7) 914 (86.4) 0.39
0 (67.2) 730 (69.0) 0.39
1 (31.2) 349 (33.0) 0.40
8 (30.9) 301 (28.4) 0.23
0 (37.1) 389 (36.8) 0.89
,261 1,346
0.43
4 (52.7) 722 (53.6)
8 (21.3) 259 (19.2)
9 (26.1) 365 (27.1)
2 (67.6) 932 (69.2) 0.38
 10.1 20.1 10.8 0.19
1 (100.0) —
— 383 (28.5)
— 404 (30.0)
— 559 (41.5)
7 (21.8) 248 (23.4) 0.37
 0.54 1.27 0.68 0.78
 0.42 3.17 0.83 0.73
 10.1 22.9 10.7 0.71
4 (40.0) 540 (40.1) 0.95
 3.7 16.5 3.6 0.74
9 (1.9) 21 (2.0) 0.63
9 (99.8) 1,345 (99.9) 0.61
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onth DAPT groups (0.3% vs. 0%, respectively) (18).
hese findings might be explained by better neointimal
overage in the early post-implant period compared with
ther DES (7).
tudy limitations. First, 1 year of clinical follow-up may
ot be sufficient to assess the late outcomes, especially the
ccurrence of very late stent thrombosis. Second, because
he patients with very high risks were not included, the
eneralized application of these results to the entire
opulation demands careful attention. A careful assess-
ent of the balance between the risk of stent thrombosis
nd the likelihood of bleeding events at an individual
atient level is required (19). Third, the study design was
ContinuedTable 3 Continued
Variables E-ZES3
Quantitative angiographic analysis
Pre-intervention
Reference vessel diameter, mm 3.0
Minimum luminal diameter, mm 1.1
Percent diameter stenosis, % 65.1
Post-intervention
Minimum luminal diameter, mm
In-stent 2.7
In-segment 2.2
Percent diameter stenosis, %
In-stent 11.1
In-segment 29.8
Values are n, mean  SD, or n (%). Analysis was performed after exc
Abbreviations as in Table 1.
Clinical Outcomes of Both Groups on a Per-Protocol AnalysisTable 4 Clinical Outcomes of Both Groups on a Per-Protocol An
Characteristics
E-ZES
(
Composite events
Primary endpoint
Death from any cause, myocardial infarction, or stent thrombosis
Death from cardiovascular cause or myocardial infarction
Each component
Death
From any cause
From cardiovascular cause
Myocardial infarction
Target vessel revascularization
Non–target vessel revascularization
Stent thrombosis, definite or probable
1 months
1–3 months
3–12 months
Bleeding
Major or minor
Major
Cerebrovascular accidents
Values are the number of events and the cumulative event rate (%). Analysis was performed after
log-rank test.
Abbreviations as in Tables 1 and 2.ot ideal: the comparator group in our trial was not
reated with a single DES type; in addition, there was no
-month versus 12-month DAPT, either within E-ZES
r within other DES patients. However, because the
ypothesis of protection by E-ZES was the main objec-
ive of this trial, and the 1:1 matched randomization
etween E-ZES and the comparative DES was per-
ormed, interpretation of the final results of the
-ZES3-month DAPT group should be viewed appro-
priate. Treatment strategies (combination of DES
duration of DAPT), neither DES types alone, nor DAPT
duration alone were evaluated in this study. Finally,
although the sample size of this study was calculated not
to be underpowered on the basis of the event rates in
h DAPT Standard Therapy p Value
3.0 0.5 0.18
1.0 0.5 0.39
.1 65.5 13.8 0.52
2.7 0.4 0.24
2.1 0.5 0.66
11.1 8.1 0.83
.8 30.7 11.7 0.76
f the patients interrupting the 3-month DAPT criteria.
is
nth DAPT
7)
Standard Therapy
(n  1,058) Difference (95% CI) p Value
6) 41 (4.7) 0.1% (2.7 to 2.4) 0.69
6) 11 (1.3) 0.7% (1.6 to 0.3) 0.27
4) 7 (0.7) 0.3% (0.9 to 0.4) 0.42
3) 8 (1.0) 0.7% (1.5 to 0.2) 0.15
2) 4 (0.4) 0.2% (0.6 to 0.3) 0.46
2) 4 (0.4) 0.2% (0.7 to 0.3) 0.46
7) 27 (3.7) 0.0% (2.5 to 2.4) 0.94
5) 11 (1.5) 0.0% (1.4 to 1.4) 0.55
2) 3 (0.3) 0.1% (0.5 to 0.3) 0.70
0
0
3
5) 10 (1.0) 0.5% (1.2 to 0.3) 0.24
2) 6 (0.6) 0.4% (0.9 to 0.2) 0.18
5) 6 (0.7) 0.2% (0.9 to 0.6) 0.80
ion of the patients with interrupting 3-month DAPT. *p values were calculated with the use of the-Mont
 0.5
 0.5
 14
 0.4
 0.5
 7.8
 11alys
3-Mo
n  99
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4 (0.
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could be underpowered as a result of a relatively lower
event rate than expected. The authors cannot know what
among many factors was responsible for the differences
from anticipated event rates.
Conclusions
E-ZES3-month DAPT could be safe and beneficial for
the selected patients with coronary artery disease who may
need to stop DAPT early after DES implantation.
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APPENDIX
For a supplementary introduction,methods, discussion, and references, aswell as
expanded information on the trial investigators, please see the online version of
this paper.
